Profusa adds a leading french critical limb ischemia surgeon to customer base

Pr. yann gouËffic and affiliates (france-pad) cover ~8% of all clti cases in france berkeley, calif, oct. 01, 2025 (globe newswire) -- profusa, inc. (“profusa” or the “company”) (nasdaq: pfsa), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual's biochemistry, announces additional growth in its customer base in europe, with a collaboration with yann gouËffic, m.d., ph.d., professor of vascular surgery in the vascular center at groupe hospitalier paris saint joseph, paris, france and a leading surgeon in the field of critical limb threatening ischemia (clti).
PFSA Ratings Summary
PFSA Quant Ranking